An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Kezar Life Sciences (NASDAQ: KZR), a biotechnology firm focused on innovative treatments for immune-mediated and oncologic disorders, announced that its Co-founder and Chief Scientific Officer, Christopher Kirk, PhD, will present at three upcoming investor conferences in September 2022. The events include the Wells Fargo Healthcare Conference in Boston on September 8, H.C. Wainwright's Global Investment Conference in New York on September 13, and Morgan Stanley's Global Healthcare Conference in New York on September 14. Webcasts will be available on the company's website post-event.
Positive
None.
Negative
None.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Christopher Kirk, PhD, Co-founder, President and Chief Scientific Officer, will participate in three upcoming investor conferences in September.
Presentation Details:
Event: 2022 Wells Fargo Healthcare Conference Location:Boston, MA Date/Time:Thursday, September 8, 2022, at 1:20 PM ET Format: Fireside Chat
Event:H.C. Wainwright 24th Annual Global Investment Conference Location:New York, NY Date/Time:Tuesday, September 13, 2022, at 11:30 AM ET Format: Podium Presentation
Event: Morgan Stanley 20th Annual Global Healthcare Conference
Location:New York, NY Date/Time:Wednesday, September 14, 2022, at9:10 AM ET Format: Fireside Chat
Webcasts from the presentations will be available on the “Events & Presentations” section of the Company’s website at www.kezarlifesciences.com. Following the events, archived webcasts will be available on the Kezar website for 90 days.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor being evaluated in a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com.
What investor conferences will Kezar Life Sciences participate in September 2022?
Kezar Life Sciences will participate in the Wells Fargo Healthcare Conference on September 8, H.C. Wainwright's Global Investment Conference on September 13, and Morgan Stanley's Global Healthcare Conference on September 14, 2022.
Who will represent Kezar Life Sciences at the upcoming conferences?
Christopher Kirk, PhD, Co-founder and Chief Scientific Officer of Kezar Life Sciences, will represent the company at the conferences in September 2022.
Where can I watch the webcasts of Kezar Life Sciences' presentations?
Webcasts of Kezar Life Sciences' presentations will be available in the 'Events & Presentations' section of their website.
What is Kezar Life Sciences' lead development asset?
Kezar Life Sciences' lead development asset is Zetomipzomib, a selective immunoproteasome inhibitor currently evaluated in a Phase 2 clinical trial for lupus nephritis.
